Sharon Natanzon

Assistant Professor. Division of Cardiology, Heart Failure. University of Florida, Jacksonville.

[Sharon Natanzon @NatanzonSharon]

Had the opportunity to talk about heart failure on @FirstCoastNews
Raising awareness is crucial to improving care and outcomes. #heartfailure
#Cardiology
#HealthAwareness
https://t.co/cVY20MxBW0

[Cristina Font, MD @CristinaFontMD]

Flail P2 with torrential MR, treated with M-TEER and reduced to trace-mild MR using two devices (MitraClip XTW and XT).

A striking before-and-after comparison.

#StructuralHeart #CardioTwitter @alizgheib @ufjaxcards

[Dipan J. Shah, MD @DipanJShah]

Multivalvular disease is challenging and remains an evidence gap. This CMR-powered study helps clarify the natural history of moderate AS with concomitant MR—a dual-valve phenotype with worse remodeling and outcomes than isolated severe AS. @JACCJournals #WhyCMR

[Dr. Filippo Cademartiri @FCademartiri]

🚨🫀 Cardiac CT is no longer just about coronary stenosis.
Photon-Counting CT is turning it into full cardiac phenotyping.

And that changes everything.

A new JACC editorial makes it clear:
👉 We are moving from coronary angiography
to
�� comprehensive myocardial + coronary characterization in one scan

This is not an upgrade.
This is a paradigm shift.

What PCCT can now do:
✔ Coronary stenosis assessment
✔ Plaque characterization
✔ LV mass + function
✔ Extracellular volume (ECV)
✔ Late iodine enhancement (LIE) for fibrosis detection
✔ Myocardial tissue characterization

👉 All in a single examination
And the numbers are impressive:
Compared with CMR:
📊 LV mass index → r = 0.963
📊 Ejection fraction → r = 0.947
📊 ECV → r = 0.868
📊 LIE vs LGE → 99–100% segment concordance
📊 Diagnostic accuracy → AUC 0.994
📊 Sensitivity 99% | Specificity 100%
Let that sink in.
The real implication?

We stop asking only:
❌ “Is there obstructive CAD?”
And start asking:

✅ What is the plaque biology?
✅ Is there fibrosis?
✅ Is this hypertrophy, amyloid, HCM, or infiltration?
✅ What is the full cardiac phenotype?
My take:

This perfectly supports what many still underestimate:
PCCT is not better coronary CTA.
It is the beginning of a new cardiovascular imaging modality.
From anatomy

➡️ to biology
From stenosis
➡️ to disease
From isolated findings
➡️ to integrated phenotyping
⚡ The future of cardiac imaging is not another test.

👉 It’s one scan that answers the real question:
What is happening to this patient’s heart?

[Sharon Natanzon @NatanzonSharon]

@DrMarthaGulati @purviparwani @ACCinTouch @dranulala @iamritu @JamalRanaMD @robmentz I think hospitals with the capabilities are already doing that. Nice to have real data to support it. It also emphasizes the crucial role of the PERT team to have a multidisciplinary discussion prior to decision.

[Montefiore Heart @MonteHeart]

Welcome to another @MonteHeart Imaging and Clinical Lecture

Friday, March 6, 2026. From 12:00 pm EST – 1:00 pm EST @salernomdphd

Link: https://t.co/YsJhZrqOzL

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Elevated Pulmonary Artery Wedge Pressure in Group 1 Pulmonary Hypertension: @CircAHA

🥸 Many patients have higher wedge + type 1 PulmHTN - this reports describes this group in detail.

😱 Take a look below:

👇👇👇👇

[Circulation @CircAHA]

Acute eosinophilic myocarditis may present without peripheral eosinophilia in up to 57.4% of cases - making endomyocardial biopsy essential, as reliance on blood eosinophils risks missed diagnosis.https://t.co/eYwjPS1ogb

[Ahmed Bennis MD 🫀 @drbennisahmed]

Machine learning-based phenotyping and assessment of treatment responses in heart failure with preserved ejection fraction

Machine learning-based algorithm identifies HFpEF phenogroups with distinct clinical features and treatment responses. This study suggests that SGLT2i and ARNI have a role in improving the outcomes in patients with metabolic comorbidities and both systolic and diastolic impairment, while calcium channel blockers were most likely to benefit HFpEF patients with atrial fibrillation

#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare
@hfcollaboratory @CircHF @TheLancet @mvaduganathan @hvanspall @BiykemB @AndrewJSauer @ankeetbhatt
https://t.co/yuN0apvOJt

[Sharon Natanzon @NatanzonSharon]

Highly recommended conference

[Daniel Berman @danielbermanmd]

Just over a month left to register for our January 2026 three-day conference at Cedars-Sinai, “Advances in Nuclear Cardiology, Cardiac CT, and Cardiac MRI,” with some of the most well-known speakers in the field. View the course agenda and register at https://t.co/JlJwc9XzEl

[Ahmed Bennis MD 🫀 @drbennisahmed]

Transthyretin amyloid cardiomyopathy: natural history and treatment response assessed by cardiovascular magnetic resonance

CMR with ECV mapping can track changes in cardiac amyloid burden and treatment response in ATTR-CM, with changes in ECV being independently associated with outcomes.

#Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare

@CMichaelGibson @DrMarthaGulati @hvanspall @Hragy @iamritu @AndrewJSauer @ankeetbhatt @biljana_parapid @AnastasiaSMihai @MasriAhmadMD

https://t.co/sW7Kz9oavQ

[Eduardo Marban, MD, PhD @MarbanLab]

Stellar @SmidtHeart faculty-driven program, featuring the best of the best! Strongly recommended for anyone interested in cardiac imaging.

[CardiovascularCorner @TrackYourHeart]

The Ultimate CPET Thread
How to Decode Dyspnea Using Physiology (Braunwald + Clinical Insights)
CPET is not just a stress test, It is a complete physiologic study of the heart, lungs, and muscles working together under stress
A 🧵

[Sharon Natanzon @NatanzonSharon]

Proud of our cardiology fellows and internal medicine residents.
@UFMedicineJax @ufjaxcards
https://t.co/HfYPfLN5IK

[CME INDIA @CMEINDIA1]

SGLT2i & UTI: Continue or Stop?

🧩 Key Question:
What happens when patients with T2DM on SGLT2 inhibitors develop a new-onset UTI?
Should therapy be continued or discontinued thereafter?

🔍 Key Finding (EHJ, 2025 | doi:10.1093/eurheartj/ehaf788)

In >61,000 T2DM patients on SGLT2i (2015–2022):
🔹 6.3% developed a new-onset UTI during follow-up.
🔹 Those with UTI had markedly higher risks of:
  🫀 CV composite events (HR 3.18; 95% CI 2.88–3.51)
  💧 Renal composite events (HR 2.51; 95% CI 2.32–2.72)

After UTI, 32% stopped SGLT2i.
 🚫 Discontinuation increased:
  🫀 CV risk → HR 1.35 (1.20–1.53)
  💧 Renal risk → HR 1.35 (1.21–1.51)
 💊 No significant reduction in recurrent UTI risk (HR 0.96).

💡 Take-Home Message

🌊 New-onset UTI is a marker of vulnerability — signalling higher cardio-renal risk.

❌ Stopping SGLT2 inhibitors post-UTI worsens CV and renal outcomes, without lowering reinfection risk.

✅ Best approach:
 – Treat UTI appropriately 🔬
 – Resume or continue SGLT2 inhibitor once infection resolves
 – Maintain long-term CV-renal protection 🌿

🩺 Clinical Insight

“UTI is a complication; discontinuation is a setback.”
Keep the molecule — protect the heart & kidney, not just the bladder. ��

Source:
�� European Heart Journal (2025): Wu M-Z et al., Urinary tract infection and continuation of sodium–glucose cotransporter-2 inhibitors in diabetic patients.
🔗
https://t.co/Zqy6uCbVCv

[HFAPresident @HFA_President]

Multimodality imaging in advanced #HeartFailure (part 2):
#HFA_ESC Clinical Consensus Statement on #MCS & #HeartTransplantation 🫀

In #advancedHF care, #CVimaging is not just diagnostic, it is longitudinal surveillance across #LVAD and post-transplant care:
📍Candidate selection, ventricular+valve function, device positioning, unloading assessment, evaluation of #RV failure & device complications
📍Graft function, perfusion & rejection evaluation, CAV monitoring

More🔗: https://t.co/1sAWgmXKkl

@escardio @EJHFEiC @ESC_Journals
@MarcoMetra @jozinetm @AlbertoAimo90 @MajaCikes @FinnGustafsson @kevin_damman @juliendreyfus1

#EchoFirst #yesCCT #whyCMR #ThinkPET

[JACC Journals @JACCJournals]

In symptomatic #nHCM, #mavacamten improved LV diastolic & LA function with modest LVH regression, but 1 in 5 demonstrated an #LVEF <50%, which reversed following therapy interruption. https://t.co/mA9ljpTTPF

#JACC #ESCCongress #WCCardio @DesaiMilindY

[JACC Journals @JACCJournals]

Treatment with #mavacamten for 48 weeks in #nHCM patients was associated with marked biomarker improvements compared with placebo. Long-term effects on remodeling, health status, and outcomes remain uncertain. https://t.co/VFe9HAYJLC

#JACC #ESCCongress #WCCardio @DesaiMilindY

[Sharon Natanzon @NatanzonSharon]

@AnnaKateBarton @EHJIMPEiC @Bgheyath @Rosh_Khat @csmcbiri @kaveh_med @JGrapsa @Sarah_Moharem @AnastasiaSMihai @DrMarthaGulati @HanCardiomd You guys look the same!!

[Sharon Natanzon @NatanzonSharon]

Fantastic representation of the @UFMedicineJax heart failure team in Heart Failure Management 2025.

[Sharon Natanzon @NatanzonSharon]

@AnnaKateBarton Congrats 👏 👏 👏 👏 👏